U.S. FDA· @FDA · X·· 1 天前精选AI 评分58
AI 导读
FDA 宣布批准一项用于既往未治疗的 III/IV 期霍奇金淋巴瘤患者的疗法，适用年龄低至 12 岁及以上。该消息由 FDA 在儿童癌症宣传月期间发布，并附有该药物获批信息的官方页面链接。
推荐理由
FDA 官方披露纳武利尤单抗联合化疗获批用于既往未治疗的 III/IV 期霍奇金淋巴瘤，读者可据此了解该适应症的最低年龄门槛。
正文
The fight against childhood cancer is one of our many missions. Treatments are key when it comes to combating the many forms of cancer that affect children. The FDA is making real progress! Recently we approved a treatment for patients as young as 12+ with previously untreated Stage III/IV Hodgkin lymphoma. #ChildhoodCancerMonth https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma
来源：U.S. FDA · x.com